Share Price and Basic Stock Data
Last Updated: December 17, 2025, 9:23 pm
| PEG Ratio | 1.16 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Jagsonpal Pharmaceuticals Ltd has carved out a notable position in the Indian pharmaceutical sector, with a market capitalization of ₹1,332 Cr. The company’s revenue trajectory reflects a blend of stability and growth, with sales reported at ₹237 Cr for FY 2023, up from ₹218 Cr the previous year. However, the latest fiscal year has shown some fluctuations, with sales for FY 2024 declining to ₹209 Cr. This dip was accompanied by a trailing twelve-month (TTM) revenue of ₹283 Cr, suggesting potential recovery as the company seems to have rebounded with sales of ₹269 Cr for FY 2025. The quarterly sales figures also indicate a certain degree of volatility, with the most recent quarter reporting ₹75 Cr, highlighting both the challenges and opportunities the company faces in maintaining consistent revenue streams. Overall, Jagsonpal appears to be in a phase of adjustment, navigating market dynamics while aiming for a stable upward trend in sales.
Profitability and Efficiency Metrics
Profitability metrics for Jagsonpal Pharmaceuticals are striking, particularly in light of their operating profit margin (OPM) which stood at 19% for FY 2025. This is a significant improvement from the 14% OPM reported in FY 2023, indicating enhanced operational efficiency. The net profit for FY 2025 reached ₹61 Cr, translating to a strong net profit margin of 20.60%, marking an impressive leap from 11.28% in FY 2023. Additionally, the company’s return on equity (ROE) at 18.6% and return on capital employed (ROCE) at 23% reflect a robust ability to generate returns from its equity and capital investments. However, the fluctuations in quarterly net profits, particularly the decline to ₹4 Cr in December 2023, underscore the need for sustained performance to avoid potential investor concerns about earnings consistency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Jagsonpal Pharmaceuticals displays a commendable strength, particularly with borrowings remaining minimal at just ₹9 Cr. This positions the company with a healthy debt-to-equity ratio, bolstering its financial stability. The interest coverage ratio (ICR) at an impressive 61.86x indicates that the company can comfortably meet its interest obligations, a comforting factor for investors. Reserves have also shown a steady increase, standing at ₹240 Cr, enhancing the company’s ability to invest in growth opportunities. The price-to-book value ratio of 5.99x may appear stretched compared to industry norms, suggesting that investors are pricing in future growth expectations. Furthermore, with a current ratio of 6.22, Jagsonpal seems well-equipped to cover its short-term liabilities, although this high liquidity may raise questions about capital efficiency.
Shareholding Pattern and Investor Confidence
The shareholding structure of Jagsonpal Pharmaceuticals reveals a strong commitment from promoters, who hold 67.54% of the company. This substantial stake indicates a level of confidence in the company’s strategic direction. However, foreign institutional investors (FIIs) and domestic institutional investors (DIIs) remain relatively modest, holding 2.12% and 0.08% respectively, which could reflect a cautious approach towards the stock. The public float stands at 30.25%, with the number of shareholders increasing significantly to 24,653, suggesting growing retail interest. The stability in promoter holdings over recent quarters, despite slight declines, may be interpreted as a positive indicator of long-term commitment. However, the limited institutional presence could also suggest potential volatility in stock price movements, as institutional investors often provide a stabilizing influence in turbulent markets.
Outlook, Risks, and Final Insight
Looking ahead, Jagsonpal Pharmaceuticals appears poised for growth, yet it faces certain risks. The company’s ability to sustain its profitability amidst fluctuating sales will be crucial, particularly with the recent dip in quarterly revenues. Moreover, while the high liquidity is reassuring, it also raises questions about capital deployment efficiency—investors may prefer to see strategic investments that enhance growth rather than holding excess cash. Additionally, the limited institutional participation could lead to increased stock volatility, especially in response to market news or earnings announcements. As such, investors might want to closely monitor the company’s quarterly performance and management’s strategic initiatives to ensure that it maintains momentum. Overall, while Jagsonpal Pharmaceuticals has demonstrated resilience and potential, careful scrutiny of its operational execution and market conditions will be essential for those considering an investment in the company.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 143 Cr. | 114 | 235/84.3 | 31.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,240 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.8 Cr. | 42.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 46.9 Cr. | 32.0 | 32.0/17.0 | 112 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,299.53 Cr | 1,144.52 | 51.48 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 61 | 61 | 60 | 55 | 60 | 58 | 47 | 43 | 61 | 75 | 74 | 59 | 76 |
| Expenses | 53 | 48 | 52 | 50 | 52 | 49 | 44 | 41 | 51 | 58 | 58 | 50 | 61 |
| Operating Profit | 7 | 13 | 9 | 5 | 9 | 8 | 3 | 3 | 10 | 16 | 16 | 9 | 14 |
| OPM % | 12% | 21% | 14% | 10% | 14% | 14% | 7% | 6% | 17% | 22% | 21% | 15% | 19% |
| Other Income | -3 | 1 | 2 | 3 | 2 | 2 | 3 | 2 | -2 | 2 | 26 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 4 | 14 | 10 | 7 | 10 | 10 | 5 | 5 | 7 | 15 | 39 | 9 | 14 |
| Tax % | 24% | 24% | 21% | 24% | 26% | 25% | 25% | 22% | 25% | 25% | 17% | 24% | 25% |
| Net Profit | 3 | 10 | 8 | 6 | 7 | 7 | 4 | 4 | 5 | 11 | 32 | 7 | 11 |
| EPS in Rs | 0.45 | 1.59 | 1.19 | 0.85 | 1.14 | 1.14 | 0.60 | 0.54 | 0.81 | 1.73 | 4.82 | 0.99 | 1.62 |
Last Updated: August 1, 2025, 7:00 pm
Below is a detailed analysis of the quarterly data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 76.00 Cr.. The value appears strong and on an upward trend. It has increased from 59.00 Cr. (Mar 2025) to 76.00 Cr., marking an increase of 17.00 Cr..
- For Expenses, as of Jun 2025, the value is 61.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 50.00 Cr. (Mar 2025) to 61.00 Cr., marking an increase of 11.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 5.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 15.00% (Mar 2025) to 19.00%, marking an increase of 4.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Mar 2025) to 25.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 4.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.62. The value appears strong and on an upward trend. It has increased from 0.99 (Mar 2025) to 1.62, marking an increase of 0.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:09 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 144 | 138 | 143 | 144 | 127 | 167 | 159 | 188 | 218 | 237 | 209 | 269 | 283 |
| Expenses | 133 | 129 | 132 | 138 | 138 | 157 | 150 | 169 | 192 | 203 | 186 | 218 | 227 |
| Operating Profit | 11 | 9 | 12 | 6 | -11 | 9 | 9 | 19 | 26 | 34 | 23 | 51 | 55 |
| OPM % | 7% | 6% | 8% | 4% | -9% | 6% | 5% | 10% | 12% | 14% | 11% | 19% | 20% |
| Other Income | 0 | 0 | 1 | 13 | 0 | 1 | 3 | 4 | 3 | 2 | 9 | 28 | 34 |
| Interest | 5 | 4 | 5 | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 8 | 9 |
| Profit before tax | 3 | 2 | 4 | 14 | -12 | 9 | 9 | 22 | 27 | 35 | 30 | 70 | 79 |
| Tax % | 16% | 30% | 20% | 18% | -1% | 20% | 16% | 22% | 29% | 23% | 25% | 21% | |
| Net Profit | 2 | 1 | 3 | 12 | -12 | 7 | 8 | 17 | 19 | 27 | 22 | 55 | 62 |
| EPS in Rs | 0.32 | 0.18 | 0.50 | 1.81 | -1.76 | 1.10 | 1.20 | 2.60 | 2.88 | 4.08 | 3.40 | 8.34 | 9.32 |
| Dividend Payout % | 62% | 22% | 8% | 2% | -2% | 9% | 17% | 15% | 56% | 49% | 59% | 30% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 200.00% | 300.00% | -200.00% | 158.33% | 14.29% | 112.50% | 11.76% | 42.11% | -18.52% | 150.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 250.00% | 100.00% | -500.00% | 358.33% | -144.05% | 98.21% | -100.74% | 30.34% | -60.62% | 168.52% |
Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| TTM: | 35% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 42% |
| 5 Years: | 38% |
| 3 Years: | 29% |
| TTM: | 87% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 75% |
| 3 Years: | 16% |
| 1 Year: | 45% |
| Return on Equity | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 16% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 8:00 am
Balance Sheet
Last Updated: December 10, 2025, 2:53 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 85 | 82 | 85 | 97 | 85 | 91 | 98 | 109 | 120 | 146 | 174 | 227 | 240 |
| Borrowings | 36 | 39 | 38 | 8 | 8 | 4 | 5 | 7 | 0 | 6 | 9 | 9 | 9 |
| Other Liabilities | 22 | 19 | 22 | 25 | 23 | 28 | 31 | 35 | 31 | 30 | 21 | 29 | 37 |
| Total Liabilities | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
| Fixed Assets | 56 | 52 | 52 | 22 | 21 | 22 | 22 | 26 | 23 | 24 | 9 | 94 | 90 |
| CWIP | 2 | 0 | 0 | 0 | 3 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 15 | 51 | 1 | 0 | 0 | 0 |
| Other Assets | 98 | 102 | 108 | 121 | 105 | 110 | 109 | 123 | 91 | 170 | 208 | 184 | 209 |
| Total Assets | 156 | 154 | 159 | 143 | 130 | 136 | 147 | 164 | 164 | 195 | 217 | 278 | 299 |
Below is a detailed analysis of the balance sheet data for Jagsonpal Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 240.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Mar 2025) to 240.00 Cr., marking an increase of 13.00 Cr..
- For Borrowings, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 29.00 Cr. (Mar 2025) to 37.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 299.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 90.00 Cr.. The value appears to be declining and may need further review. It has decreased from 94.00 Cr. (Mar 2025) to 90.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 209.00 Cr.. The value appears strong and on an upward trend. It has increased from 184.00 Cr. (Mar 2025) to 209.00 Cr., marking an increase of 25.00 Cr..
- For Total Assets, as of Sep 2025, the value is 299.00 Cr.. The value appears strong and on an upward trend. It has increased from 278.00 Cr. (Mar 2025) to 299.00 Cr., marking an increase of 21.00 Cr..
Notably, the Reserves (240.00 Cr.) exceed the Borrowings (9.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -30.00 | -26.00 | -2.00 | -19.00 | 5.00 | 4.00 | 12.00 | 26.00 | 28.00 | 14.00 | 42.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 115 | 119 | 106 | 100 | 73 | 45 | 49 | 25 | 26 | 32 | 19 | 18 |
| Inventory Days | 173 | 176 | 246 | 295 | 307 | 164 | 191 | 134 | 122 | 82 | 68 | 58 |
| Days Payable | 29 | 42 | 60 | 56 | 54 | 59 | 76 | 82 | 76 | 66 | 35 | 37 |
| Cash Conversion Cycle | 259 | 252 | 292 | 339 | 325 | 150 | 164 | 77 | 72 | 48 | 53 | 39 |
| Working Capital Days | 64 | 68 | 72 | 154 | 149 | 67 | 55 | 32 | 59 | 34 | 52 | 9 |
| ROCE % | 6% | 5% | 7% | 3% | -10% | 9% | 9% | 18% | 20% | 25% | 17% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF | 83 | 0.04 | 0 | 83 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 8.26 | 8.49 | 10.20 | 7.48 | 6.51 |
| Diluted EPS (Rs.) | 8.22 | 8.46 | 10.20 | 7.48 | 6.51 |
| Cash EPS (Rs.) | 9.56 | 9.13 | 10.66 | 8.06 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 46.96 | 43.55 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 36.08 | 70.88 | 60.65 | 49.95 | 46.54 |
| Dividend / Share (Rs.) | 2.50 | 5.00 | 5.00 | 4.00 | 1.00 |
| Revenue From Operations / Share (Rs.) | 40.47 | 78.94 | 90.36 | 86.30 | 71.74 |
| PBDIT / Share (Rs.) | 8.92 | 12.23 | 15.22 | 11.12 | 8.96 |
| PBIT / Share (Rs.) | 7.70 | 11.61 | 14.76 | 10.54 | 8.76 |
| PBT / Share (Rs.) | 10.52 | 11.30 | 13.29 | 10.43 | 8.35 |
| Net Profit / Share (Rs.) | 8.34 | 8.50 | 10.20 | 7.48 | 6.51 |
| PBDIT Margin (%) | 22.05 | 15.49 | 16.84 | 12.88 | 12.48 |
| PBIT Margin (%) | 19.02 | 14.70 | 16.34 | 12.20 | 12.21 |
| PBT Margin (%) | 25.99 | 14.31 | 14.70 | 12.08 | 11.63 |
| Net Profit Margin (%) | 20.60 | 10.76 | 11.28 | 8.66 | 9.07 |
| Return on Networth / Equity (%) | 23.11 | 11.98 | 16.81 | 15.92 | 14.95 |
| Return on Capital Employeed (%) | 20.26 | 15.50 | 23.10 | 20.55 | 18.54 |
| Return On Assets (%) | 19.89 | 10.34 | 13.70 | 11.62 | 10.38 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
| Asset Turnover Ratio (%) | 1.08 | 1.01 | 1.30 | 1.36 | 1.21 |
| Current Ratio (X) | 6.22 | 10.42 | 5.97 | 3.24 | 2.98 |
| Quick Ratio (X) | 5.64 | 9.63 | 5.22 | 2.37 | 2.25 |
| Inventory Turnover Ratio (X) | 17.80 | 1.24 | 1.24 | 1.36 | 1.31 |
| Dividend Payout Ratio (NP) (%) | 23.89 | 58.31 | 0.00 | 53.50 | 15.35 |
| Dividend Payout Ratio (CP) (%) | 20.83 | 54.29 | 0.00 | 49.63 | 14.91 |
| Earning Retention Ratio (%) | 76.11 | 41.69 | 0.00 | 46.50 | 84.65 |
| Cash Earning Retention Ratio (%) | 79.17 | 45.71 | 0.00 | 50.37 | 85.09 |
| Interest Coverage Ratio (X) | 61.86 | 39.74 | 96.57 | 102.18 | 21.61 |
| Interest Coverage Ratio (Post Tax) (X) | 38.24 | 28.60 | 74.08 | 69.70 | 16.71 |
| Enterprise Value (Cr.) | 1305.18 | 591.93 | 644.85 | 795.42 | 154.96 |
| EV / Net Operating Revenue (X) | 4.86 | 2.84 | 2.72 | 3.52 | 0.82 |
| EV / EBITDA (X) | 22.02 | 18.30 | 16.17 | 27.31 | 6.60 |
| MarketCap / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| Retention Ratios (%) | 76.10 | 41.68 | 0.00 | 46.49 | 84.64 |
| Price / BV (X) | 5.99 | 3.95 | 4.78 | 6.68 | 1.83 |
| Price / Net Operating Revenue (X) | 5.34 | 3.54 | 3.21 | 3.63 | 1.11 |
| EarningsYield | 0.03 | 0.03 | 0.03 | 0.02 | 0.08 |
After reviewing the key financial ratios for Jagsonpal Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.00, marking a decrease of 3.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.26. This value is within the healthy range. It has decreased from 8.49 (Mar 24) to 8.26, marking a decrease of 0.23.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.22. This value is within the healthy range. It has decreased from 8.46 (Mar 24) to 8.22, marking a decrease of 0.24.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.56. This value is within the healthy range. It has increased from 9.13 (Mar 24) to 9.56, marking an increase of 0.43.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 36.08. It has decreased from 70.88 (Mar 24) to 36.08, marking a decrease of 34.80.
- For Dividend / Share (Rs.), as of Mar 25, the value is 2.50. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 2.50, marking a decrease of 2.50.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 40.47. It has decreased from 78.94 (Mar 24) to 40.47, marking a decrease of 38.47.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 8.92. This value is within the healthy range. It has decreased from 12.23 (Mar 24) to 8.92, marking a decrease of 3.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. It has decreased from 11.61 (Mar 24) to 7.70, marking a decrease of 3.91.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.52. This value is within the healthy range. It has decreased from 11.30 (Mar 24) to 10.52, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.34. This value is within the healthy range. It has decreased from 8.50 (Mar 24) to 8.34, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 15.49 (Mar 24) to 22.05, marking an increase of 6.56.
- For PBIT Margin (%), as of Mar 25, the value is 19.02. This value is within the healthy range. It has increased from 14.70 (Mar 24) to 19.02, marking an increase of 4.32.
- For PBT Margin (%), as of Mar 25, the value is 25.99. This value is within the healthy range. It has increased from 14.31 (Mar 24) to 25.99, marking an increase of 11.68.
- For Net Profit Margin (%), as of Mar 25, the value is 20.60. This value exceeds the healthy maximum of 10. It has increased from 10.76 (Mar 24) to 20.60, marking an increase of 9.84.
- For Return on Networth / Equity (%), as of Mar 25, the value is 23.11. This value is within the healthy range. It has increased from 11.98 (Mar 24) to 23.11, marking an increase of 11.13.
- For Return on Capital Employeed (%), as of Mar 25, the value is 20.26. This value is within the healthy range. It has increased from 15.50 (Mar 24) to 20.26, marking an increase of 4.76.
- For Return On Assets (%), as of Mar 25, the value is 19.89. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 19.89, marking an increase of 9.55.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.08. It has increased from 1.01 (Mar 24) to 1.08, marking an increase of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 6.22. This value exceeds the healthy maximum of 3. It has decreased from 10.42 (Mar 24) to 6.22, marking a decrease of 4.20.
- For Quick Ratio (X), as of Mar 25, the value is 5.64. This value exceeds the healthy maximum of 2. It has decreased from 9.63 (Mar 24) to 5.64, marking a decrease of 3.99.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 17.80. This value exceeds the healthy maximum of 8. It has increased from 1.24 (Mar 24) to 17.80, marking an increase of 16.56.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 58.31 (Mar 24) to 23.89, marking a decrease of 34.42.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 20.83. This value is within the healthy range. It has decreased from 54.29 (Mar 24) to 20.83, marking a decrease of 33.46.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.11. This value exceeds the healthy maximum of 70. It has increased from 41.69 (Mar 24) to 76.11, marking an increase of 34.42.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 79.17. This value exceeds the healthy maximum of 70. It has increased from 45.71 (Mar 24) to 79.17, marking an increase of 33.46.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 61.86. This value is within the healthy range. It has increased from 39.74 (Mar 24) to 61.86, marking an increase of 22.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 38.24. This value is within the healthy range. It has increased from 28.60 (Mar 24) to 38.24, marking an increase of 9.64.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,305.18. It has increased from 591.93 (Mar 24) to 1,305.18, marking an increase of 713.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.86. This value exceeds the healthy maximum of 3. It has increased from 2.84 (Mar 24) to 4.86, marking an increase of 2.02.
- For EV / EBITDA (X), as of Mar 25, the value is 22.02. This value exceeds the healthy maximum of 15. It has increased from 18.30 (Mar 24) to 22.02, marking an increase of 3.72.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For Retention Ratios (%), as of Mar 25, the value is 76.10. This value exceeds the healthy maximum of 70. It has increased from 41.68 (Mar 24) to 76.10, marking an increase of 34.42.
- For Price / BV (X), as of Mar 25, the value is 5.99. This value exceeds the healthy maximum of 3. It has increased from 3.95 (Mar 24) to 5.99, marking an increase of 2.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.34. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 24) to 5.34, marking an increase of 1.80.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jagsonpal Pharmaceuticals Ltd:
- Net Profit Margin: 20.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 20.26% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 23.11% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 38.24
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 30.8 (Industry average Stock P/E: 51.48)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 20.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Innov8 3rd Floor, New Delhi Delhi 110020 | cs@jagsonpal.com http://www.jagsonpal.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajpal Singh Kochhar | Chairman Emeritus |
| Mr. Harsha Raghavan | Chairman & Non-Exe.Director |
| Mr. Manish Gupta | Managing Director |
| Mr. Prithipal Singh Kochhar | Non Executive Director |
| Mr. Debasis Bikash Nandy | Independent Director |
| Ms. Radhika Madhukar Dudhat | Independent Director |
| Ms. Pallavi Dinodia Gupta | Independent Director |
FAQ
What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd?
Jagsonpal Pharmaceuticals Ltd's intrinsic value (as of 17 December 2025) is 176.32 which is 12.28% lower the current market price of 201.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,346 Cr. market cap, FY2025-2026 high/low of 302/193, reserves of ₹240 Cr, and liabilities of 299 Cr.
What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?
The Market Cap of Jagsonpal Pharmaceuticals Ltd is 1,346 Cr..
What is the current Stock Price of Jagsonpal Pharmaceuticals Ltd as on 17 December 2025?
The current stock price of Jagsonpal Pharmaceuticals Ltd as on 17 December 2025 is 201.
What is the High / Low of Jagsonpal Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Jagsonpal Pharmaceuticals Ltd stocks is 302/193.
What is the Stock P/E of Jagsonpal Pharmaceuticals Ltd?
The Stock P/E of Jagsonpal Pharmaceuticals Ltd is 30.8.
What is the Book Value of Jagsonpal Pharmaceuticals Ltd?
The Book Value of Jagsonpal Pharmaceuticals Ltd is 38.0.
What is the Dividend Yield of Jagsonpal Pharmaceuticals Ltd?
The Dividend Yield of Jagsonpal Pharmaceuticals Ltd is 1.24 %.
What is the ROCE of Jagsonpal Pharmaceuticals Ltd?
The ROCE of Jagsonpal Pharmaceuticals Ltd is 23.0 %.
What is the ROE of Jagsonpal Pharmaceuticals Ltd?
The ROE of Jagsonpal Pharmaceuticals Ltd is 18.6 %.
What is the Face Value of Jagsonpal Pharmaceuticals Ltd?
The Face Value of Jagsonpal Pharmaceuticals Ltd is 2.00.